CN1524590A - 一种药物洗脱介入医疗器械及其制备方法 - Google Patents
一种药物洗脱介入医疗器械及其制备方法 Download PDFInfo
- Publication number
- CN1524590A CN1524590A CNA031155960A CN03115596A CN1524590A CN 1524590 A CN1524590 A CN 1524590A CN A031155960 A CNA031155960 A CN A031155960A CN 03115596 A CN03115596 A CN 03115596A CN 1524590 A CN1524590 A CN 1524590A
- Authority
- CN
- China
- Prior art keywords
- medical device
- interventional medical
- medicament elution
- medicine
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000010828 elution Methods 0.000 title claims abstract description 17
- 239000011248 coating agent Substances 0.000 claims abstract description 25
- 238000000576 coating method Methods 0.000 claims abstract description 25
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920000052 poly(p-xylylene) Polymers 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 8
- 230000008021 deposition Effects 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229960004588 cilostazol Drugs 0.000 claims description 5
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 5
- 241001597008 Nomeidae Species 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 229940127218 antiplatelet drug Drugs 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims description 3
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 claims description 3
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims description 3
- 229960000556 fingolimod Drugs 0.000 claims description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- -1 polytetrafluoroethylene Polymers 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000010410 layer Substances 0.000 abstract description 15
- 239000011247 coating layer Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 5
- 238000007740 vapor deposition Methods 0.000 abstract description 4
- 239000003054 catalyst Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 208000001778 Coronary Occlusion Diseases 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical class CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 150000007984 tetrahydrofuranes Chemical class 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (10)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031155960A CN100435880C (zh) | 2003-02-28 | 2003-02-28 | 一种药物洗脱介入医疗器械及其制备方法 |
JP2004548875A JP2005531391A (ja) | 2002-06-27 | 2003-06-25 | 薬剤放出ステント |
AU2003280437A AU2003280437A1 (en) | 2002-06-27 | 2003-06-25 | Drug eluting stent |
PCT/CN2003/000489 WO2004002367A1 (fr) | 2002-06-27 | 2003-06-25 | Stent eluant des medicaments |
EP03739968A EP1516597A4 (en) | 2002-06-27 | 2003-06-25 | MEDICINES ELUTIONSSTENT |
US10/943,636 US20050043788A1 (en) | 2002-06-27 | 2004-09-17 | Drug-eluting stent |
US10/943,633 US20050033414A1 (en) | 2002-06-27 | 2004-09-17 | Drug-eluting stent with multi-layer coatings |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031155960A CN100435880C (zh) | 2003-02-28 | 2003-02-28 | 一种药物洗脱介入医疗器械及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1524590A true CN1524590A (zh) | 2004-09-01 |
CN100435880C CN100435880C (zh) | 2008-11-26 |
Family
ID=34284353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031155960A Expired - Lifetime CN100435880C (zh) | 2002-06-27 | 2003-02-28 | 一种药物洗脱介入医疗器械及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100435880C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721753B (zh) * | 2009-12-23 | 2014-04-09 | 天津大学 | 无机有机防腐生物相容性复合涂层的可吸收镁合金支架及其制备方法 |
CN105030390A (zh) * | 2005-04-05 | 2015-11-11 | 万能医药公司 | 可降解的植入式医疗装置 |
CN105828805A (zh) * | 2013-08-07 | 2016-08-03 | 学校法人近畿大学 | 纳米粒子和纳米粒子组合物以及用于生产纳米粒子和纳米粒子组合物的方法 |
CN106512188A (zh) * | 2016-12-13 | 2017-03-22 | 天津飞捷科技有限公司 | 机电一体化靶向药物释放介入类医疗器械及其制备方法 |
CN110547897A (zh) * | 2019-09-04 | 2019-12-10 | 中国人民解放军总医院 | 血管支架装置 |
CN111035485A (zh) * | 2019-12-16 | 2020-04-21 | 西南交通大学 | 一种血管支架及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
JP4215188B2 (ja) * | 1997-12-22 | 2009-01-28 | インターシア セラピューティクス,インコーポレイティド | 薬剤供給を調節するデバイスのための速度調節膜 |
US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
CN1223385C (zh) * | 2002-12-31 | 2005-10-19 | 中国科学院金属研究所 | 一种具有控制释放治疗性药物的心血管支架 |
-
2003
- 2003-02-28 CN CNB031155960A patent/CN100435880C/zh not_active Expired - Lifetime
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105030390A (zh) * | 2005-04-05 | 2015-11-11 | 万能医药公司 | 可降解的植入式医疗装置 |
US10350093B2 (en) | 2005-04-05 | 2019-07-16 | Elixir Medical Corporation | Degradable implantable medical devices |
CN101721753B (zh) * | 2009-12-23 | 2014-04-09 | 天津大学 | 无机有机防腐生物相容性复合涂层的可吸收镁合金支架及其制备方法 |
CN105828805A (zh) * | 2013-08-07 | 2016-08-03 | 学校法人近畿大学 | 纳米粒子和纳米粒子组合物以及用于生产纳米粒子和纳米粒子组合物的方法 |
CN105828805B (zh) * | 2013-08-07 | 2020-06-23 | 学校法人近畿大学 | 纳米粒子和纳米粒子组合物以及用于生产纳米粒子和纳米粒子组合物的方法 |
CN106512188A (zh) * | 2016-12-13 | 2017-03-22 | 天津飞捷科技有限公司 | 机电一体化靶向药物释放介入类医疗器械及其制备方法 |
CN110547897A (zh) * | 2019-09-04 | 2019-12-10 | 中国人民解放军总医院 | 血管支架装置 |
CN110547897B (zh) * | 2019-09-04 | 2021-04-23 | 中国人民解放军总医院 | 血管支架装置 |
CN111035485A (zh) * | 2019-12-16 | 2020-04-21 | 西南交通大学 | 一种血管支架及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100435880C (zh) | 2008-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8021678B2 (en) | Implantable medical device with polymer coating in a surface area to volume ratio providing surface erosion characteristics | |
US8753663B2 (en) | Drug eluting coatings for medical implants | |
US6994867B1 (en) | Biocompatible carrier containing L-arginine | |
CN101795719B (zh) | 药物缓释性支架 | |
US6918929B2 (en) | Drug-polymer coated stent with pegylated styrenic block copolymers | |
US7144419B2 (en) | Drug-polymer coated stent with blended phenoxy and styrenic block copolymers | |
JP4796506B2 (ja) | 医薬組成物 | |
US20100055145A1 (en) | Stent coatings for reducing late stent thrombosis | |
JP5982688B2 (ja) | 埋込み型デバイス用の吸収性コーティング | |
US20070244284A1 (en) | Durable Biocompatible Controlled Drug Release Polymeric Coatings for Medical Devices | |
JP2011502195A (ja) | 熱安定性が改善した、薬物送達ステントマトリックスのためのポリマーブレンド | |
JP6387359B2 (ja) | ラパマイシン誘導体を含む埋め込み型医療用デバイスの製造方法 | |
US20100119578A1 (en) | Extracellular matrix modulating coatings for medical devices | |
WO2008098418A1 (en) | Intracoronary stent with asymmetric drug releasing controlled coating | |
US20040147999A1 (en) | Stent with epoxy primer coating | |
KR20110009055A (ko) | 항혈전성 컨쥬게이트를 갖는 의료 장치용 코팅 | |
CN100435880C (zh) | 一种药物洗脱介入医疗器械及其制备方法 | |
CN101641059A (zh) | 一种不对称药物控释涂层冠脉内支架 | |
US20050004646A1 (en) | Energy-activated adhesion layer for drug-polymer coated stent | |
US20080234657A1 (en) | Methods for contributing to cardiovascular treatments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHANGHAI MICROPORT MEDICAL EQUIPMENT (GROUP) CO., Free format text: FORMER NAME: WEICHUANG MEDICAL EQUIPMENT (SHANGHAI) CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 201203, 501, Newton Road, Zhangjiang hi tech park, Shanghai, Pudong Patentee after: SHANGHAI MICROPORT MEDICAL (GROUP) Co.,Ltd. Address before: 201203, 501, Newton Road, Zhangjiang hi tech park, Shanghai, Pudong Patentee before: MICROPORT MEDICAL (SHANGHAI) Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20081126 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Hong Xiaopeng Document name: Notice of Termination of Patent Rights |